You are here

Share:

Synthesis and Characterization of Bismuth Beads for Trans Arterial Chemo Embolization Under Computed Tomography (CT) Guidance

Summary
The National Institute of Health - Clinical Center (NIH-CC) seeks licensing and/or co-development of a method for real-time tracking of blood vessel occlusion in loco-regional treatments using bismuth-based beads.
NIH Reference Number
E-136-2016
Product Type
Keywords
  • Trans-arterial Chemoembolization, TACE, Bismus, Image-able Bead, Blood Vessel Occlusion, Loco-regional Treatment, Negussie
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

Existing microsphere technologies are used as therapy for certain cancers. The therapy is by way of occlusion, when the microspheres are delivered into blood vessels that feed a tumor. The physical dimensions of the microspheres occlude the blood supply and thus, killing the tumor. Some microspheres have also been modified to bind protein, elute drugs, and reduce inflammatory reactions as part of the therapy. However, one technical short-coming of existing microsphere technology is a limited capability to be visualized in real-time. The inability to visualize embolic microspheres during treatment and post treatment could lead to complications and the need for additional treatments, thereby increasing the chance of additional complications.

Researchers at the National Institutes of Health – Clinical Center (NIH-CC) have developed a technology that uses bismuth-based beads with a hydrophilic polymer to allow for real-time tracking with a computed tomography (CT) scanner of loco regional treatments. Visualization capability is important for confirmation of proper delivery to the targeted vessels and monitoring of treatment after surgery. The real-time CT visualization capability helps solve a major shortcoming of current embolic microsphere treatments. The beads can be differentiated from other clinical imaging contrast agents – making it easier for physicians to identify the location of the loco-regional treatment, and may improve therapeutic outcomes.

Potential Commercial Applications
  • Trackable beads for loco-regional treatments 
Competitive Advantages
  • Capable of being tracked in real-time
  • Capable of being differentiated from conventional iodine contrast
Development Stage
Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 62/459,242 , Filed 15 Feb 2017
  • U.S. Patent Filed: U.S. Patent Application Number PCT/US2017/059406 , Filed 31 Oct 2017
Therapeutic Area
Updated
Thursday, August 16, 2018